James Quella - Catalent Director
| CTLT Stock | USD 56.05 0.57 1.03% |
Director
Mr. James A. Quella is Independent Director of the Company. Mr. Quella was a Senior Managing Director and Senior Operating Partner in the Corporationrationrate Private Equity group of The Blackstone Group L.P. through June 2013. Mr. Quella was responsible for monitoring the strategy and operational performance of Blackstones portfolio companies and providing direct assistance in the oversight of large investments. He was also a member of the firms Private Equity Investment Committee. Currently, Mr. Quella serves as a Senior Advisor to the Private Equity Group of Blackstone and continues to be involved in a few key portfolio companies as a board member and executive advisor, as well as participating in selected portfolio review processes and due diligence. Prior to joining Blackstone in 2004, Mr. Quella was a Managing Director and Senior Operating Partner with DLJ Merchant Banking PartnersCSFB Private Equity. Prior to that, Mr. Quella worked at Mercer Management Consulting and Strategic Planning Associates, its predecessor firm, where he served as a senior consultant to CEOs and senior management teams, and was CoVice Chairman with shared responsibility for overall management of the firm. Mr. Quella received a B.A. in International Studies from the University of ChicagoUniversity of WisconsinMadison and an M.B.A. with deans honors from the University of Chicago. He is also the coauthor of Profit Patterns 30 Ways to Anticipate and Profit from the Strategic Forces Reshaping Your Business since 2009.
| Age | 68 |
| Tenure | 15 years |
| Address | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Catalent Management Efficiency
Return On Tangible Assets is likely to gain to -0.03 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. At this time, Catalent's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 157.5 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 6.2 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Norah Barlow | Evotec SE ADR | N/A | |
| Robert Breyer | Alkermes Plc | 73 | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Edward Kay | Eagle Pharmaceuticals | N/A | |
| Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
| Lynda Reid | Evotec SE ADR | N/A | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Hamish Stevens | Evotec SE ADR | N/A | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Richard Edlin | Eagle Pharmaceuticals | 57 | |
| Anthony Quirk | Evotec SE ADR | N/A | |
| Robert Glenning | Eagle Pharmaceuticals | 57 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| David Anstice | Alkermes Plc | 69 | |
| Grainne Troute | Evotec SE ADR | N/A | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| Alain Schreiber | Eagle Pharmaceuticals | 58 | |
| Paul Mitchell | Alkermes Plc | 64 | |
| Michael Graves | Eagle Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0075 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Walsh, CFO and Executive VP | ||
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Bruce McEvoy, Director | ||
| Aris Gennadios, President - Softgel Technologies | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| James Quella, Director | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Gregory Lucier, Independent Director | ||
| Scott Houlton, President - Development and Clinical Services | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Matti Masanovich, Senior CFO | ||
| Martin Carroll, Director | ||
| Julien Meissonnier, VP Officer | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Lance Miyamoto, Senior Vice President - Human Resources | ||
| Rosemary Crane, Independent Director | ||
| Sharon Johnson, Sr. VP of Quality, Product Devel., and Regulatory Affairs | ||
| Joseph JD, General VP | ||
| Peter Zippelius, Independent Director | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Stephen Leonard, Sr. VP of Global Operations | ||
| Chinh Chu, Chairman of the Board | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Christine Dolan, Senior Vice President - Product Development | ||
| Christa Kreuzburg, Independent Director | ||
| William Downie, Sr. VP of Global Marketing and Sales | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Lucier Gregory, Director | ||
| Barry Littlejohns, President - Advanced Delivery Technologies | ||
| Melvin Booth, Director | ||
| Jack Stahl, Lead Independent Director | ||
| Uwe Rohrhoff, Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0075 | ||||
| Profit Margin | (0.32) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 14.81 B | ||||
| Shares Outstanding | 180.97 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 7.51 M | ||||
| Price To Earning | 17.80 X | ||||
| Price To Book | 2.76 X |
Catalent Investors Sentiment
The influence of Catalent's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Catalent. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Catalent's public news can be used to forecast risks associated with an investment in Catalent. The trend in average sentiment can be used to explain how an investor holding Catalent can time the market purely based on public headlines and social activities around Catalent. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalent's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalent's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Catalent's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Catalent.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catalent in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catalent's short interest history, or implied volatility extrapolated from Catalent options trading.
Pair Trading with Catalent
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalent position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalent will appreciate offsetting losses from the drop in the long position's value.Moving against Catalent Stock
| 0.59 | EVO | Evotec SE ADR Earnings Call Tomorrow | PairCorr |
| 0.57 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Catalent could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalent when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalent - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalent to buy it.
The correlation of Catalent is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalent moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalent moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalent can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Catalent Stock please use our How to Invest in Catalent guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Catalent Stock analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Catalent's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalent. If investors know Catalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.15) | Earnings Share (7.18) | Revenue Per Share 22.579 | Quarterly Revenue Growth (0.11) | Return On Assets (0.01) |
The market value of Catalent is measured differently than its book value, which is the value of Catalent that is recorded on the company's balance sheet. Investors also form their own opinion of Catalent's value that differs from its market value or its book value, called intrinsic value, which is Catalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalent's market value can be influenced by many factors that don't directly affect Catalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.